Imunopatologia do SARS-CoV-2 e análise dos imunizantes no território brasileiro

SARS-COV-2 belongs to the family Coronaviridae and is responsible for the disease called COVID-19, considered a global public health problem. The present study aimed to describe the immunopathology of COVID-19 and the vaccines currently available. This is a descriptive analysis study with a qualitative approach, on the immunopathology of COVID-19 and the vaccines currently available. In Brazil, the National Health Surveillance Agency approved on an emergency basis on January 17, 2021, the CoronaVac immunizers from the Chinese laboratory SINOVAC in partnership with the Butantan Institute, located in the state of Sao Paulo, and the AstraZeneca from the University of Oxford in England in partnership with Fiocruz in Rio de Janeiro. It should be noted that they still have other vaccines developed that are awaiting emergency approval by ANVISA. However, in the current context, those with storage at 2 to 8oC become viable in the Brazilian climate, commonly for immunizers of other diseases without the need for deep freezers. It is concluded that vaccines are guarantees of immunological efficacy to protect the population against the disease.